Algenis SpA
🇨🇱Chile
- Country
- 🇨🇱Chile
- Ownership
- Holding
- Established
- 2002-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.algenis.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)Proof of Principle Study Evaluating Gonyautoxins NEURO SERUM, on Chemotherapy-induced Peripheral Neuropathy
Phase 1
Recruiting
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: Placebo PSP NEURO SERUM
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 52
- Registration Number
- NCT05052398
- Locations
- 🇧🇷
Nucleo de Oncologia da Bahia, Salvador, Bahia, Brazil
🇧🇷Oncoclínicas Vitória, Vitória, Espírito Santo, Brazil
🇧🇷Oncoclinicas do Brasil Servicios Medicos SA, Belo Horizonte, Minas Gerais, Brazil
Gonyautoxin 2/3 in the Treatment of Acute Back Pain: A Clinical Proof-of-concept Study
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 30
- Registration Number
- NCT04799041
- Locations
- 🇨🇱
Hospital San José SSMN, Santiago, Metropolitana, Chile
NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Algenis SpA
- Target Recruit Count
- 30
- Registration Number
- NCT03655522
News
No news found